Table 1.
Demographic, clinical, and neuropathological characteristics across clinical-pathological diagnostic groups for cases contributing precuneus samples to the study
| Demographic, clinical, and neuropathological characteristics | Clinical-pathological diagnostic
groups and groupwise comparisons |
||||||
|---|---|---|---|---|---|---|---|
| NCI (n = 19) | MCI (n =10) | mAD (n = 7) | sAD (n =10) | Total (n = 46) | p | Groupwise comparisons | |
| Age (y) at death | |||||||
| Mean ± SD | 85.9 ± 5.4 | 87.2 ± 5.4 | 89.1 ± 4.3 | 80.5 ± 7.3 | 85.4 ± 6.3 | 0.03a | sAD<mAD |
| (Range) | (77.3–95.2) | (79.4–94.0) | (83.1–94.5) | (62–90.0) | (62–94.5) | ||
| Education (y) | |||||||
| Mean ± SD | 17.6 ± 3.5 | 17.3 ± 2.1 | 17.7 ± 2.9 | 15.5 ± 3.2 | 17.1 ± 3.1 | 0.36a | ANOVA not significant |
| (Range) | (10–25) | (14–20) | (14–23) | (12–20) | (10–25) | ||
| MMSE | |||||||
| Mean ± SD | 28.6 ± 1.5 | 26.0 ± 3.5 | 22.6 ± 3.2 | 7.5 ± 6.7 | 22.2 ± 9.3 | <0.001a | NCI>mAD; NCI, MCI > sAD |
| (Range) | (25–30) | (19–29) | (17–27) | (1–21) | (1–30) | ||
| PMI (h) | |||||||
| Mean ± SD | 6.3 ± 2.5 | 6.1 ± 2.9 | 5.5 ± 2.5 | 8.2 ± 3.6 | 6.6 ± 2.9 | 0.19a | ANOVA not significant |
| (Range) | (3.1–13) | (2.8–11.5) | (1.5–8.2) | (3–14) | (1.5–14) | ||
| Number (%) males | 8 (42) | 3 (30) | 2 (29) | 6 (60) | 19 (41) | 0.49b | Chi-square not significant |
| APOE ε4 (carrier/noncarrier) | 4/15 | 3/7 | 4/3 | 5/5* | 16/30* | 0.21b | Chi-square not significant |
| CERAD diagnosis | |||||||
| No AD | 5 | 1 | 0 | 0 | 6 | <0.001b | NCI, MCI < sAD |
| Possible | 3 | 1 | 0 | 0 | 4 | ||
| Probable | 10 | 6 | 4 | 0 | 20 | ||
| Definite | 1 | 2 | 3 | 10 | 16 | ||
| Braak stage | |||||||
| 0-II | 7 | 2 | 0 | 0 | 9 | <0.001b | NCI, MCI, mAD < sAD |
| III-IV | 11 | 6 | 5 | 0 | 22 | ||
| V-VI | 1 | 2 | 2 | 10 | 15 | ||
| NIA-RI diagnosis | |||||||
| No AD | 0 | 0 | 0 | 0 | 0 | <0.001b | NCI, MCI < sAD |
| Low | 11 | 3 | 0 | 0 | 14 | ||
| Intermediate | 8 | 6 | 5 | 1 | 20 | ||
| High | 0 | 1 | 2 | 9 | 12 | ||
a
Kruskal-Wallis one-way analysis of variance
b
Chi-square analysis.
AD, Alzheimer’s disease; ANOVA, one-way analysis of variance; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; MCI, mild cognitive impairment; mAD, mild to moderate AD; NIA-RI, National Institute on Aging-Reagan Institute; NCI, no cognitive impairment; PMI, postmortem interval; sAD, moderate to severe AD; SD, standard deviation.
∗
APOE ε4 data not available for one case.